Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Persistent mediastinal FDG uptake on PET-CT after frontline therapy for Hodgkin lymphoma: biopsy, treat or observe?

Novo M, Nowakowski GS, Habermann TM, Witzig TE, Micallef IN, Johnston PB, Inwards DJ, Botto B, Ristow KM, Young JR, Vitolo U, Ansell SM.

Leuk Lymphoma. 2019 Sep 26:1-10. doi: 10.1080/10428194.2019.1663422. [Epub ahead of print]

PMID:
31556355
2.

Outcome of transformed follicular lymphoma worsens according to the timing of transformation and to the number of previous therapies. A retrospective multicenter study on behalf of Fondazione Italiana Linfomi (FIL).

Rusconi C, Anastasia A, Chiarenza A, Marcheselli L, Cavallo F, Rattotti S, Botto B, Ferrari A, Nassi L, Pagani C, Meli E, Arcaini L, Federico M, Rossi G; Fondazione Italiana Linfomi (FIL).

Br J Haematol. 2019 May;185(4):713-717. doi: 10.1111/bjh.15816. Epub 2019 Feb 21.

PMID:
30793297
3.

Yttrium-90 ibritumomab tiuxetan (Zevalin) followed by BEAM (Z-BEAM) conditioning regimen and autologous stem cell transplantation (ASCT) in relapsed or refractory high-risk B-cell non-Hodgkin lymphoma (NHL): a single institution Italian experience.

Ciochetto C, Botto B, Passera R, Bellò M, Benevolo G, Boccomini C, Castellino A, Chiappella A, Freilone R, Nicolosi M, Orsucci L, Pecoraro C, Pregno P, Bisi G, Vitolo U.

Ann Hematol. 2018 Sep;97(9):1619-1626. doi: 10.1007/s00277-018-3328-3. Epub 2018 Apr 16.

PMID:
29663029
4.

Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma.

Pellegrini C, Broccoli A, Pulsoni A, Rigacci L, Patti C, Gini G, Mannina D, Tani M, Rusconi C, Romano A, Vanazzi A, Botto B, Santoro A, Hoaus S, Rigolin GM, Musto P, Mazza P, Molica S, Corradini P, Fama A, Gaudio F, Merli M, Ronconi F, Gritti G, Vallisa D, Tosi P, Liberati AM, Pinto A, Pavone V, Gherlinzoni F, Bianchi MP, Volpetti S, Trentin L, Goldaniga MC, Bonfichi M, De Renzo A, Schiavotto C, Spina M, Carella AM, Stefoni V, Argnani L, Zinzani PL.

Oncotarget. 2017 May 23;8(53):91703-91710. doi: 10.18632/oncotarget.18114. eCollection 2017 Oct 31.

5.

Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma.

Broccoli A, Pellegrini C, Di Rocco A, Puccini B, Patti C, Gini G, Mannina D, Tani M, Rusconi C, Romano A, Vanazzi A, Botto B, Carlo-Stella C, Hohaus S, Musto P, Mazza P, Molica S, Corradini P, Fama A, Gaudio F, Merli M, Gravetti A, Gritti G, Arcari A, Tosi P, Liberati AM, Pinto A, Pavone V, Gherlinzoni F, Naso V, Volpetti S, Trentin L, Goldaniga MC, Bonfichi M, De Renzo A, Schiavotto C, Spina M, Storti S, Carella AM, Stefoni V, Argnani L, Zinzani PL.

Haematologica. 2017 Nov;102(11):1931-1935. doi: 10.3324/haematol.2017.171355. Epub 2017 Aug 3.

6.

Prognostic models for primary mediastinal (thymic) B-cell lymphoma derived from 18-FDG PET/CT quantitative parameters in the International Extranodal Lymphoma Study Group (IELSG) 26 study.

Ceriani L, Martelli M, Conconi A, Zinzani PL, Ferreri AJM, Botto B, Stelitano C, Gotti M, Cabras MG, Rigacci L, Giovanella L, Zucca E, Johnson PWM.

Br J Haematol. 2017 Aug;178(4):588-591. doi: 10.1111/bjh.14728. Epub 2017 May 9.

PMID:
28485042
7.

Follicular Lymphoma: The Management of Elderly Patient.

Castellino A, Santambrogio E, Nicolosi M, Botto B, Boccomini C, Vitolo U.

Mediterr J Hematol Infect Dis. 2017 Jan 1;9(1):e2017009. doi: 10.4084/MJHID.2017.009. eCollection 2017. Review.

8.

Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi.

Zaja F, Ferrero S, Stelitano C, Ferrari A, Salvi F, Arcari A, Musuraca G, Botto B, Spina M, Cellini C, Patti C, Liberati AM, Minotto C, Pileri SA, Ceccarelli M, Volpetti S, Ferranti A, Drandi D, Montechiarello E, Ladetto M, Carmichael J, Fanin R.

Haematologica. 2017 May;102(5):e203-e206. doi: 10.3324/haematol.2016.154211. Epub 2017 Jan 12. No abstract available.

9.

Potential Benefit of Involved-Field Radiotherapy for Patients With Relapsed-Refractory Hodgkin's Lymphoma With Incomplete Response Before Autologous Stem Cell Transplantation.

Levis M, Piva C, Filippi AR, Botto B, Gavarotti P, Pregno P, Nicolosi M, Freilone R, Parvis G, Gottardi D, Vitolo U, Ricardi U.

Clin Lymphoma Myeloma Leuk. 2017 Jan;17(1):14-22. doi: 10.1016/j.clml.2016.09.008. Epub 2016 Sep 17.

PMID:
27727134
10.

Post-ABVD/pre-radiotherapy (18)F-FDG-PET provides additional prognostic information for early-stage Hodgkin lymphoma: a retrospective analysis on 165 patients.

Ciammella P, Filippi AR, Simontacchi G, Buglione M, Botto B, Mangoni M, Iotti C, Merli F, Marcheselli L, Bisi G, Ricardi U, Versari A.

Br J Radiol. 2016;89(1061):20150983. doi: 10.1259/bjr.20150983. Epub 2016 Mar 24.

11.

B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL).

Balzarotti M, Brusamolino E, Angelucci E, Carella AM, Vitolo U, Russo E, Congiu A, Gotti M, Massidda S, Botto B, Annechini G, Spina M, Re A, Zilioli VR, Merli F, Salvi F, Stelitano C, Bonfichi M, Rodari M, Murru R, Magagnoli M, Anastasia A, Mazza R, Giordano L, Santoro A.

Leuk Lymphoma. 2016 Oct;57(10):2375-81. doi: 10.3109/10428194.2016.1140161. Epub 2016 Feb 15.

PMID:
26879066
12.

Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma.

Ceriani L, Martelli M, Zinzani PL, Ferreri AJ, Botto B, Stelitano C, Gotti M, Cabras MG, Rigacci L, Gargantini L, Merli F, Pinotti G, Mannina D, Luminari S, Stathis A, Russo E, Cavalli F, Giovanella L, Johnson PW, Zucca E.

Blood. 2015 Aug 20;126(8):950-6. doi: 10.1182/blood-2014-12-616474. Epub 2015 Jun 18.

PMID:
26089397
13.

Interim PET After Two ABVD Cycles in Early-Stage Hodgkin Lymphoma: Outcomes Following the Continuation of Chemotherapy Plus Radiotherapy.

Simontacchi G, Filippi AR, Ciammella P, Buglione M, Saieva C, Magrini SM, Livi L, Iotti C, Botto B, Vaggelli L, Re A, Merli F, Ricardi U.

Int J Radiat Oncol Biol Phys. 2015 Aug 1;92(5):1077-1083. doi: 10.1016/j.ijrobp.2015.04.021. Epub 2015 Apr 17.

PMID:
26031367
14.

Prognostic roles of absolute monocyte and absolute lymphocyte counts in patients with advanced-stage follicular lymphoma in the rituximab era: an analysis from the FOLL05 trial of the Fondazione Italiana Linfomi.

Marcheselli L, Bari A, Anastasia A, Botto B, Puccini B, Dondi A, Carella AM, Alvarez I, Chiarenza A, Arcari A, Salvi F, Federico M.

Br J Haematol. 2015 May;169(4):544-51. doi: 10.1111/bjh.13332. Epub 2015 Mar 29.

PMID:
25817296
15.

PBSC mobilization in lymphoma patients: analysis of risk factors for collection failure and development of a predictive score based on the kinetics of circulating CD34+ cells and WBC after chemotherapy and G-CSF mobilization.

Rossi G, Skert C, Morello E, Almici C, Arcaini L, Basilico C, Cavalli L, Botto B, Castelli A, Pica G, Ripamonti F, Salvi F, Carella AM, Gaidano G, Levis A, Nosari A, Russo D, Vitolo U.

Hematol Oncol. 2015 Sep;33(3):125-32. doi: 10.1002/hon.2148. Epub 2014 May 29.

PMID:
24890497
16.

Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial.

Vitolo U, Chiappella A, Franceschetti S, Carella AM, Baldi I, Inghirami G, Spina M, Pavone V, Ladetto M, Liberati AM, Molinari AL, Zinzani P, Salvi F, Fattori PP, Zaccaria A, Dreyling M, Botto B, Castellino A, Congiu A, Gaudiano M, Zanni M, Ciccone G, Gaidano G, Rossi G; Fondazione Italiana Linfomi.

Lancet Oncol. 2014 Jun;15(7):730-7. doi: 10.1016/S1470-2045(14)70191-3. Epub 2014 May 13.

PMID:
24831981
17.

Involved-site image-guided intensity modulated versus 3D conformal radiation therapy in early stage supradiaphragmatic Hodgkin lymphoma.

Filippi AR, Ciammella P, Piva C, Ragona R, Botto B, Gavarotti P, Merli F, Vitolo U, Iotti C, Ricardi U.

Int J Radiat Oncol Biol Phys. 2014 Jun 1;89(2):370-5. doi: 10.1016/j.ijrobp.2014.01.041. Epub 2014 Mar 7.

PMID:
24613810
18.

Safety and efficacy of (90) yttrium-ibritumomab-tiuxetan for untreated follicular lymphoma patients. An Italian cooperative study.

Ibatici A, Pica GM, Nati S, Vitolo U, Botto B, Ciochetto C, Petrini M, Galimberti S, Ciabatti E, Orciuolo E, Zinzani PL, Cascavilla N, Guolo F, Fraternali Orcioni G, Carella AM.

Br J Haematol. 2014 Mar;164(5):710-6. doi: 10.1111/bjh.12695. Epub 2013 Dec 17.

PMID:
24344981
19.

Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italiana Linfomi.

Vitolo U, Ladetto M, Boccomini C, Baldini L, De Angelis F, Tucci A, Botto B, Chiappella A, Chiarenza A, Pinto A, De Renzo A, Zaja F, Castellino C, Bari A, Alvarez De Celis I, Evangelista A, Parvis G, Gamba E, Lobetti-Bodoni C, Ciccone G, Rossi G.

J Clin Oncol. 2013 Sep 20;31(27):3351-9. doi: 10.1200/JCO.2012.44.8290. Epub 2013 Aug 19.

PMID:
23960180
20.

Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials.

Zinzani PL, Viviani S, Anastasia A, Vitolo U, Luminari S, Zaja F, Corradini P, Spina M, Brusamolino E, Gianni AM, Santoro A, Botto B, Derenzini E, Pellegrini C, Argnani L.

Haematologica. 2013 Aug;98(8):1232-6. doi: 10.3324/haematol.2012.083048. Epub 2013 May 3.

21.

90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-LineIndolent trial.

Morschhauser F, Radford J, Van Hoof A, Botto B, Rohatiner AZ, Salles G, Soubeyran P, Tilly H, Bischof-Delaloye A, van Putten WL, Kylstra JW, Hagenbeek A.

J Clin Oncol. 2013 Jun 1;31(16):1977-83. doi: 10.1200/JCO.2012.45.6400. Epub 2013 Apr 1.

PMID:
23547079
22.

Interim positron emission tomography and clinical outcome in patients with early stage Hodgkin lymphoma treated with combined modality therapy.

Filippi AR, Botticella A, Bellò M, Botto B, Castiglione A, Gavarotti P, Gottardi D, Parvis G, Bisi G, Levis A, Vitolo U, Ricardi U.

Leuk Lymphoma. 2013 Jun;54(6):1183-7. doi: 10.3109/10428194.2012.735667. Epub 2012 Nov 1.

PMID:
23035692
23.

Final results of a multicenter trial addressing role of CSF flow cytometric analysis in NHL patients at high risk for CNS dissemination.

Benevolo G, Stacchini A, Spina M, Ferreri AJ, Arras M, Bellio L, Botto B, Bulian P, Cantonetti M, Depaoli L, Di Renzo N, Di Rocco A, Evangelista A, Franceschetti S, Godio L, Mannelli F, Pavone V, Pioltelli P, Vitolo U, Pogliani EM; Fondazione Italiana Linfomi.

Blood. 2012 Oct 18;120(16):3222-8. doi: 10.1182/blood-2012-04-423095. Epub 2012 Aug 27.

PMID:
22927246
24.

Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP.

Pregno P, Chiappella A, Bellò M, Botto B, Ferrero S, Franceschetti S, Giunta F, Ladetto M, Limerutti G, Menga M, Nicolosi M, Priolo G, Puccini B, Rigacci L, Salvi F, Vaggelli L, Passera R, Bisi G, Vitolo U.

Blood. 2012 Mar 1;119(9):2066-73. doi: 10.1182/blood-2011-06-359943. Epub 2012 Jan 10.

PMID:
22234681
25.

The efficacy and safety of bortezomib and dexamethasone as a maintenance therapy in patients with advanced multiple myeloma who are responsive to salvage bortezomib-containing regimens.

Benevolo G, Larocca A, Gentile M, Pregno P, Gay F, Botto B, Frairia C, Evangelista A, Morabito F, Boccadoro M, Vitolo U, Palumbo A.

Cancer. 2011 May 1;117(9):1884-90. doi: 10.1002/cncr.25743. Epub 2010 Nov 18.

26.

Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients.

Zinzani PL, Rossi G, Franceschetti S, Botto B, Di Rocco A, Cabras MG, Petti MC, Stefoni V, Broccoli A, Fanti S, Pellegrini C, Montini GC, Gandolfi L, Derenzini E, Argnani L, Fina M, Tucci A, Bottelli C, Pileri S, Baccarani M.

Clin Cancer Res. 2010 Aug 1;16(15):3998-4004. doi: 10.1158/1078-0432.CCR-10-0162. Epub 2010 Jun 11.

27.

FDG-PET in the assessment of patients with follicular lymphoma treated by ibritumomab tiuxetan Y 90: multicentric study.

Lopci E, Santi I, Derenzini E, Fonti C, Savelli G, Bertagna F, Bellò M, Botto B, Huglo D, Morschhauser F, Zinzani P, Fanti S.

Ann Oncol. 2010 Sep;21(9):1877-83. doi: 10.1093/annonc/mdq024. Epub 2010 Feb 10.

PMID:
20147744
28.

Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study.

Vitolo U, Chiappella A, Angelucci E, Rossi G, Liberati AM, Cabras MG, Botto B, Ciccone G, Gaidano G, Falchi L, Freilone R, Novero D, Orsucci L, Pavone V, Pogliani E, Rota-Scalabrini D, Salvi F, Tonso A, Tucci A, Levis A; Gruppo Italiano Multiregionale Linfomi e Leucemie (GIMURELL).

Haematologica. 2009 Sep;94(9):1250-8. doi: 10.3324/haematol.2009.007005. Epub 2009 Jul 7.

29.

Long term results of a randomized study performed by Intergruppo Italiano Linfomi comparing Mini-CEOP vs P-VEBEC in elderly patients with diffuse large B-cell lymphoma.

Merli F, Bertini M, Luminari S, Mozzana R, Botto B, Liberati AM, Baldini L, Cabras G, Di Vito F, Orsucci L, Naglieri E, Polimeno G, Marcheselli L, Pennese E, Vitolo U, Federico M, Gallo E.

Leuk Lymphoma. 2007 Feb;48(2):367-73.

PMID:
17325898
30.

Quality of life assessment in elderly patients with aggressive non-Hodgkin's Lymphoma treated with anthracycline-containing regimens. Report of a prospective study by the Intergruppo Italiano Linfomi.

Merli F, Bertini M, Luminari S, Mozzana R, Bertè R, Trottini M, Stelitano C, Botto B, Pizzuti M, Quintana G, De Paoli A, Federico M; Intergruppo Italiano Linfomi.

Haematologica. 2004 Aug;89(8):973-8.

31.

Point mutations of the BCL-6 gene: clinical and prognostic correlation in B-diffuse large cell lymphoma.

Vitolo U, Botto B, Capello D, Vivenza D, Zagonel V, Gloghini A, Novero D, Parvis G, Calvi R, Ariatti C, Milan I, Bertini M, Boccomini C, Freilone R, Pregno P, Orsucci L, Palestro G, Saglio G, Carbone A, Gallo E, Gaidano G.

Leukemia. 2002 Feb;16(2):268-75.

32.

Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma.

Esteller M, Gaidano G, Goodman SN, Zagonel V, Capello D, Botto B, Rossi D, Gloghini A, Vitolo U, Carbone A, Baylin SB, Herman JG.

J Natl Cancer Inst. 2002 Jan 2;94(1):26-32.

PMID:
11773279
33.

Short term treatment with Escherichia coli recombinant human granulocyte-macrophage-colony stimulating factor prior to chemotherapy for Hodgkin disease.

Aglietta M, Montemurro F, Fagioli F, Volta C, Botto B, Cantonetti M, Racanelli V, Teofili L, Ferrara R, Amadori S, Castoldi GL, Dammacco F, Levis A.

Cancer. 2000 Jan 15;88(2):454-60.

PMID:
10640980
34.

Distribution and pattern of BCL-6 mutations throughout the spectrum of B-cell neoplasia.

Capello D, Vitolo U, Pasqualucci L, Quattrone S, Migliaretti G, Fassone L, Ariatti C, Vivenza D, Gloghini A, Pastore C, Lanza C, Nomdedeu J, Botto B, Freilone R, Buonaiuto D, Zagonel V, Gallo E, Palestro G, Saglio G, Dalla-Favera R, Carbone A, Gaidano G.

Blood. 2000 Jan 15;95(2):651-9.

PMID:
10627476
35.

Burkitt's lymphomas in adults: retrospective analysis of 30 cases treated with two different schemes.

Calvi R, Bertini M, Boccomini C, Botto B, Orsucci L, Vitolo U.

Haematologica. 1999 Apr;84(4):383-4. No abstract available.

36.

Rearrangements of bcl-6, bcl-2, c-myc and 6q deletion in B-diffuse large-cell lymphoma: clinical relevance in 71 patients.

Vitolo U, Gaidano G, Botto B, Volpe G, Audisio E, Bertini M, Calvi R, Freilone R, Novero D, Orsucci L, Pastore C, Capello D, Parvis G, Sacco C, Zagonel V, Carbone A, Mazza U, Palestro G, Saglio G, Resegotti L.

Ann Oncol. 1998 Jan;9(1):55-61.

PMID:
9541684
37.

Mantle cell lymphoma: a retrospective study on 27 patients. Clinical features and natural history.

Bertini M, Rus C, Freilone R, Botto B, Calvi R, Novero D, Orsucci L, Vitolo U, Palestro G, Resegotti L.

Haematologica. 1998 Apr;83(4):312-6.

38.

Idarubicin in patients with diffuse large cell lymphomas: a randomized trial comparing VACOP-B (A = doxorubicin) vs VICOP-B (I = idarubicin).

Bertini M, Freilone R, Botto B, Calvi R, Gallamini A, Gatti AM, Liberati AM, Meneghini V, Orlandi E, Orsucci L, Pizzuti M, Rota Scalabrini D, Salvi F, Todeschini G, Vitolo U, Resegotti L.

Haematologica. 1997 May-Jun;82(3):309-13.

39.

Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high-risk diffuse large-cell lymphoma.

Vitolo U, Cortellazzo S, Liberati AM, Freilone R, Falda M, Bertini M, Botto B, Cinieri S, Levis A, Locatelli F, Lovisone E, Marmont F, Pizzuti M, Rossi A, Viero P, Barbui T, Grignani F, Resegotti L.

J Clin Oncol. 1997 Feb;15(2):491-8.

PMID:
9053470
40.

Combined modality treatment with a weekly brief chemotherapy (ACOP-B) followed by locoregional radiotherapy in localized-stage intermediate- to high-grade non-Hodgkin's lymphoma.

Freilone R, Botto B, Vitolo U, Bertini M, Audisio E, Calvi R, Cucchi M, De Crescenzo A, Gallamini A, Ghio R, Griso L, Levis A, Massara G, Orsucci L, Ricardi U, Rota Scalabrini D, Salvi F, Secondo V, Resegotti L.

Ann Oncol. 1996 Nov;7(9):919-24.

PMID:
9006742
41.

Results of a low aggressivity chemotherapy regimen (CVP/CEB) in elderly Hodgkin's disease patients.

Levis A, Depaoli L, Bertini M, Botto B, Ciravegna G, Freilone R, Gallamini A, Gavarotti P, Ricardi U, Rota Scalabrini D, Salomone A, Salvi F, Vitolo U, Pileri A, Sannazzari GL, Resegotti L.

Haematologica. 1996 Sep-Oct;81(5):450-6.

42.

The treatment of elderly patients with aggressive non-Hodgkin's lymphomas: feasibility and efficacy of an intensive multidrug regimen.

Bertini M, Freilone R, Vitolo U, Botto B, Ciotti R, Cinieri S, Di Nota A, Di Vito F, Levis A, Orsucci L, Pini M, Rota-Scalabrini D, Todeschini G, Resegotti L.

Leuk Lymphoma. 1996 Aug;22(5-6):483-93.

PMID:
8882962
43.

Molecular heterogeneity of B-lineage diffuse large cell lymphoma.

Volpe G, Vitolo U, Carbone A, Pastore C, Bertini M, Botto B, Audisio E, Freilone R, Novero D, Cappia S, De Giuli P, Mazza U, Resegotti L, Palestro G, Saglio G, Gaidano G.

Genes Chromosomes Cancer. 1996 May;16(1):21-30.

PMID:
9162193
44.

Risk for British travellers of acquiring hepatitis A.

Behrens RH, Collins M, Botto B, Heptonstall J.

BMJ. 1995 Jul 15;311(6998):193. No abstract available.

45.

P-VEBEC: a new 8-weekly schedule with or without rG-CSF for elderly patients with aggressive non-Hodgkin's lymphoma (NHL).

Bertini M, Freilone R, Vitolo U, Botto B, Pizzuti M, Gavarotti P, Levis A, Orlandi E, Orsucci L, Pini M, et al.

Ann Oncol. 1994 Dec;5(10):895-900.

PMID:
7535080
46.

[PRESENT STATUS OF SURGERY].

BOTTO B.

Minerva Med. 1963 Nov 14;54:3494-5. Italian. No abstract available.

PMID:
14121439

Supplemental Content

Support Center